Literature DB >> 1445687

[A new inclusion complex of silibinin and beta-cyclodextrins: in vitro dissolution kinetics and in vivo absorption in comparison with traditional formulations].

M Arcari1, A Brambilla, A Brandt, R Caponi, G Corsi, M Di Rella, F Solinas, W P Wachter.   

Abstract

The very low bioavailability of silybinin, the main constituent of silymarin, so far prevented the development of an oral pharmaceutical specialty based on this active ingredient. To overcome this difficulty, an inclusion complex between Silybinin and beta-Cyclodextrin was prepared. The new complex was compared in vitro tests (dissolution rate) and in a in vivo test (rat bile elimination) with silybinin, silymarin and one traditional formulation based on silybinin. The results show a dramatic increase in the dissolution rate of the complex (> 90% within 5 min) respect to the silybinin that confirm to be practically insoluble (< 5%). The in vivo results agree with the dissolution rates; after administration of the silybinin complex p.o., the silybinin concentration in the rat bile was near 20 times more than after administration of silybinin as is or in a traditional formulation. In the last two cases, the silybinin concentration was even 6 times less than after administration of the same amount of silymarin. These data show that the beta-CD complex solved the problem of the bioavailability of silybinin which, in the traditional formulation utilised as reference, proved to be not bioavailable.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1445687

Source DB:  PubMed          Journal:  Boll Chim Farm        ISSN: 0006-6648


  8 in total

Review 1.  The use of silymarin in the treatment of liver diseases.

Authors:  R Saller; R Meier; R Brignoli
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Antioxidant, DNA cleavage, and cellular effects of silibinin and a new oxovanadium(IV)/silibinin complex.

Authors:  Luciana G Naso; Evelina G Ferrer; Nataliya Butenko; Isabel Cavaco; Luis Lezama; Teófilo Rojo; Susana B Etcheverry; Patricia A M Williams
Journal:  J Biol Inorg Chem       Date:  2011-03-12       Impact factor: 3.358

3.  Comparative pharmacokinetics of silipide and silymarin in rats.

Authors:  P Morazzoni; A Montalbetti; S Malandrino; G Pifferi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Jul-Sep       Impact factor: 2.441

Review 4.  Silybin, a Major Bioactive Component of Milk Thistle (Silybum marianum L. Gaernt.)-Chemistry, Bioavailability, and Metabolism.

Authors:  Michal Bijak
Journal:  Molecules       Date:  2017-11-10       Impact factor: 4.411

5.  Enhancement of Silymarin Anti-fibrotic Effects by Complexation With Hydroxypropyl (HPBCD) and Randomly Methylated (RAMEB) β-Cyclodextrins in a Mouse Model of Liver Fibrosis.

Authors:  Sami Gharbia; Cornel Balta; Hildegard Herman; Marcel Rosu; Judit Váradi; Ildikó Bácskay; Miklós Vecsernyés; Szilvia Gyöngyösi; Ferenc Fenyvesi; Sorina N Voicu; Miruna S Stan; Roxana E Cristian; Anca Dinischiotu; Anca Hermenean
Journal:  Front Pharmacol       Date:  2018-08-13       Impact factor: 5.810

6.  Silymarin-laden PVP-PEG polymeric composite for enhanced aqueous solubility and dissolution rate: Preparation and in vitro characterization.

Authors:  Abid Mehmood Yousaf; Usman Rashid Malik; Yasser Shahzad; Tariq Mahmood; Talib Hussain
Journal:  J Pharm Anal       Date:  2018-09-19

Review 7.  Silymarin (milk thistle extract) as a therapeutic agent in gastrointestinal cancer.

Authors:  Maryam Fallah; Amirhossein Davoodvandi; Shahin Nikmanzar; Sarehnaz Aghili; Seyed Mohammad Ali Mirazimi; Michael Aschner; Amir Rashidian; Michael R Hamblin; Mohsen Chamanara; Navid Naghsh; Hamed Mirzaei
Journal:  Biomed Pharmacother       Date:  2021-08-13       Impact factor: 6.529

8.  Silymarin-loaded solid nanoparticles provide excellent hepatic protection: physicochemical characterization and in vivo evaluation.

Authors:  Kwan Yeol Yang; Du Hyeong Hwang; Abid Mehmood Yousaf; Dong Wuk Kim; Young-Jun Shin; Ok-Nam Bae; Yong-Il Kim; Jong Oh Kim; Chul Soon Yong; Han-Gon Choi
Journal:  Int J Nanomedicine       Date:  2013-08-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.